KORU Medical Systems, Inc. (KRMD)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $160.49M
Last updated: Nov 17, 2026 at 11:04 AM ET
KORU Medical Systems, Inc. (KRMD) Financials: Revenue, Profit and Cash Flow
KORU Medical Systems reported revenue of $41.13M for the fiscal year ended Dec 31, 2025, up 22.2% from the year before. That year, net income was -$2.64M with a net margin of -6.4%, operating cash flow was $462.40K and free cash flow was -$470.11K. The quarter ended Sep 30, 2026 had revenue of $11.57M and net income of $218.10K.
Revenue and Margins
The operating margin was -7.2% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $12.29M, a compound annual rate of 14.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $41.13M | +22.2% | 62.3% | -7.2% | -6.4% |
| Dec 2024 | $33.65M | +18.0% | 63.4% | -19.2% | -18.0% |
| Dec 2023 | $28.52M | +2.2% | 58.6% | -36.0% | -48.2% |
| Dec 2022 | $27.90M | +18.8% | 55.1% | -38.6% | -31.0% |
| Dec 2021 | $23.49M | -2.8% | 58.6% | -29.9% | -19.4% |
| Dec 2020 | $24.18M | +4.4% | 61.8% | -5.2% | -5.0% |
| Dec 2019 | $23.16M | +33.5% | 64.1% | 2.5% | 2.4% |
| Dec 2018 | $17.35M | +8.6% | 62.3% | 6.7% | 5.2% |
| Dec 2017 | $15.98M | +30.0% | 59.2% | 9.3% | 6.8% |
| Dec 2016 | $12.29M | N/A | 61.6% | -6.0% | -4.4% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.13M | $33.65M | $28.52M | $27.90M | $23.49M | $24.18M | $23.16M | $17.35M | $15.98M | $12.29M |
| Cost of revenue | $15.52M | $12.31M | $11.81M | $12.53M | $9.72M | $9.24M | $8.31M | $6.54M | $6.52M | $4.72M |
| Gross profit | $25.60M | $21.33M | $16.71M | $15.37M | $13.77M | $14.94M | $14.85M | $10.81M | $9.46M | $7.57M |
| Research and development | $4.39M | $5.26M | $5.74M | $4.96M | $2.47M | $1.30M | $740.48K | $241.12K | $60.70K | $237.49K |
| Operating income | -$2.97M | -$6.45M | -$10.27M | -$10.78M | -$7.03M | -$1.25M | $585.68K | $1.16M | $1.48M | -$736.25K |
| Net income | -$2.64M | -$6.07M | -$13.74M | -$8.66M | -$4.56M | -$1.21M | $564.35K | $910.57K | $1.09M | -$535.00K |
| EBITDA | -$1.81M | -$5.18M | -$8.90M | -$10.09M | -$5.90M | $1.61M | $4.34M | $2.37M | $1.88M | -$474.20K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.57M | $12.05M | $11.76M | $10.90M | $10.40M | $10.19M | $9.64M | $8.84M | $8.18M | $8.43M | $8.20M | $7.19M |
| Gross profit | $7.55M | $7.85M | $7.03M | $6.82M | $6.26M | $6.48M | $6.05M | $5.56M | $5.19M | $5.48M | $5.10M | $4.33M |
| Operating income | $187.12K | $626.99K | -$864.92K | -$547.10K | -$867.68K | -$312.65K | -$1.25M | -$1.59M | -$1.70M | -$1.19M | -$1.96M | -$2.20M |
| Net income | $218.10K | $252.45K | -$807.08K | -$486.86K | -$777.97K | -$206.87K | -$1.17M | -$1.56M | -$1.58M | -$988.72K | -$1.94M | -$7.47M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $538.36K by $8.33M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $28.20M | $27.22M | $28.46M | $42.33M | $41.29M | $39.92M | $13.88M | $10.55M | $9.28M | $8.17M |
| Current assets | $19.99M | $19.13M | $20.26M | $29.80M | $37.32M | $37.53M | $11.88M | $9.03M | $7.93M | $6.78M |
| Cash and equivalents | $8.87M | $9.58M | $11.48M | $17.41M | $25.33M | $27.32M | $5.87M | $3.74M | $3.97M | $3.31M |
| Total liabilities | $11.15M | $10.40M | $8.11M | $11.01M | $4.79M | $3.76M | $2.65M | $1.58M | $1.61M | $1.49M |
| Short-term debt | $538.36K | $787.00K | $792.20K | $877.46K | $604.14K | $143.94K | $142.18K | N/A | N/A | N/A |
| Shareholder equity | $17.05M | $16.81M | $20.35M | $31.33M | $36.50M | $36.16M | $11.24M | $8.96M | $7.67M | $6.68M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $28.78T | $27.96M | $28.59M | $28.20M | $27.10M | $25.52M | $27.22M | $27.22M | $27.39M | $27.30M | $27.50M | $28.46M |
| Total liabilities | $9.39T | $9.91M | $11.67M | $11.15M | $10.64M | $8.99M | $10.87M | $10.40M | $9.66M | $8.60M | $8.38M | $8.11M |
| Cash and equivalents | $7.36T | $8.29M | $8.77M | $8.87M | $8.46M | $8.05M | $8.74M | $9.58M | $8.81M | $10.46M | $10.82M | $11.48M |
| Shareholder equity | $19.40T | $18.05M | $16.92M | $17.05M | $16.46M | $16.53M | $16.35M | $16.81M | $17.73M | $18.70M | $19.12M | $20.35M |
Cash Flow
In the fiscal year ended Dec 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $462.40K | -$319.72K | -$4.89M | -$5.40M | -$4.32M | -$743.32K | $320.62K | $1.48M | $899.91K | -$331.62K |
| Capital expenditures | $932.52K | $1.30M | $814.60K | $2.80M | $375.23K | $1.06M | $425.54K | $481.17K | $218.33K | $415.13K |
| Free cash flow | -$470.11K | -$1.62M | -$5.71M | -$8.21M | -$4.69M | -$1.80M | -$104.92K | $998.50K | $681.59K | -$746.75K |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | $184.77K | N/A | N/A | N/A |
| Investing cash flow | -$949.79K | -$1.33M | -$814.60K | -$2.80M | -$366.17K | -$1.04M | $1.31M | -$1.73M | -$219.28K | -$416.33K |
| Financing cash flow | -$221.35K | -$248.53K | -$218.87K | $279.49K | $2.71M | $23.22M | $501.30K | $14.43K | -$19.36K | -$140.74K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$882.83K | $216.11K | $14.66K | $1.09M | $65.46K | -$460.34K | -$237.47K | $939.62K | -$923.95K | $11.34K | -$346.72K | $1.10M |
| Capital expenditures | $268.22K | $577.37K | $89.89K | $407.78K | $52.49K | $28.81K | $443.44K | $43.57K | $1.08M | $124.28K | $133.08K | $196.05K |
| Free cash flow | -$1.15M | -$361.25K | -$75.22K | $686.97K | $12.97K | -$489.15K | -$680.90K | $896.05K | -$2.01M | -$112.95K | -$479.80K | $900.75K |
Frequently Asked Questions About KRMD
What is KORU Medical Systems' annual revenue?
KORU Medical Systems reported revenue of $41.13M for the fiscal year ended Dec 31, 2025.
How fast is KORU Medical Systems' revenue growing?
Revenue was up 22.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 13.8%.
Is KORU Medical Systems profitable?
No. KORU Medical Systems reported net income of -$2.64M for the fiscal year ended Dec 31, 2025, with a net margin of -6.4%.
How much free cash flow does KRMD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $462.40K minus capital expenditures of $932.52K produced free cash flow of -$470.11K.
How much debt does KORU Medical Systems have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $538.36K and cash and equivalents of $8.87M.
KRMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors